Article Text
PDF
Abstract
Omalizumab is an anti-IgE monoclonal antibody used in severe allergic asthma. Herein, we describe a case of eosinophilic granulomatosis with polyangiitis, which manifested 3 months after initiation of omalizumab therapy, while maintenance corticosteroid therapy dose was unchanged.
- asthma
- drugs: respiratory system
- vasculitis
- respiratory system
Statistics from Altmetric.com
Footnotes
Contributors LNC acquired the information for the case report from the patients notes and was the primary author of the report. He coordinated attaining the patient perspective and consent from the patient. AP revised the case write up and helped write about the background to the case, as well as contributing to the discussion. DS supervised this report. He is the consultant in charge of the patient’s care, and revised the case report, giving approval for it’s submission. We all agree to be accountable for the article and to ensure that all questions regarding the accuracy or integrity of the article are investigated and resolved.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.